These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 2551985)
1. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin. Cadroy Y; Harker LA; Hanson SR J Lab Clin Med; 1989 Oct; 114(4):349-57. PubMed ID: 2551985 [TBL] [Abstract][Full Text] [Related]
2. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo. Cadroy Y; Horbett TA; Hanson SR J Lab Clin Med; 1989 Apr; 113(4):436-48. PubMed ID: 2522978 [TBL] [Abstract][Full Text] [Related]
3. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates. Cadroy Y; Hanson SR; Harker LA Thromb Haemost; 1993 Oct; 70(4):631-5. PubMed ID: 8115989 [TBL] [Abstract][Full Text] [Related]
4. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition. Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274 [TBL] [Abstract][Full Text] [Related]
5. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis. Bossavy JP; Sakariassen KS; Barret A; Boneu B; Cadroy Y Thromb Haemost; 1998 Jan; 79(1):162-8. PubMed ID: 9459343 [TBL] [Abstract][Full Text] [Related]
6. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model. Cadroy Y; Houghten RA; Hanson SR J Clin Invest; 1989 Sep; 84(3):939-44. PubMed ID: 2760221 [TBL] [Abstract][Full Text] [Related]
7. Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222. Ireland H; Lane DA; Flynn A; Pegrum AC; Curtis JR Thromb Haemost; 1988 Apr; 59(2):240-7. PubMed ID: 2838924 [TBL] [Abstract][Full Text] [Related]
8. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis. Diquélou A; Dupouy D; Cariou R; Sakariassen KS; Boneu B; Cadroy Y Thromb Haemost; 1995 Nov; 74(5):1286-92. PubMed ID: 8607111 [TBL] [Abstract][Full Text] [Related]
9. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model. Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787 [TBL] [Abstract][Full Text] [Related]
10. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Kelly AB; Marzec UM; Krupski W; Bass A; Cadroy Y; Hanson SR; Harker LA Blood; 1991 Mar; 77(5):1006-12. PubMed ID: 1995089 [TBL] [Abstract][Full Text] [Related]
11. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative. Kaiser B; Hauptmann J; Markwardt F Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis--evidence for an anticoagulant-independent mechanism. Barbanti M; Calanni F; Milani MR; Marchi E; Semeraro N; Colucci M Thromb Haemost; 1993 Feb; 69(2):147-51. PubMed ID: 8456427 [TBL] [Abstract][Full Text] [Related]
13. Dermatan sulfate inhibition of fibrin-rich thrombus formation in nonhuman primates. Cadroy Y; Hanson SR; Harker LA Arterioscler Thromb; 1993 Aug; 13(8):1213-7. PubMed ID: 8343496 [TBL] [Abstract][Full Text] [Related]
14. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases. Melo FR; Mourão PA Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401 [TBL] [Abstract][Full Text] [Related]
15. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity. Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972 [TBL] [Abstract][Full Text] [Related]
16. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Bratt G; Törnebohm E; Granqvist S; Aberg W; Lockner D Thromb Haemost; 1985 Dec; 54(4):813-7. PubMed ID: 3911482 [TBL] [Abstract][Full Text] [Related]
17. In vivo inhibition of acute platelet-dependent thrombosis in a baboon model by Bay U3405, a thromboxane A2-receptor antagonist. Kotzé HF; Lamprecht S; Badenhorst PN; van Wyk V; Roodt JP; Alexander K Thromb Haemost; 1993 Oct; 70(4):672-5. PubMed ID: 8115994 [TBL] [Abstract][Full Text] [Related]
18. The influence of low molecular weight heparin in combination with dihydroergotamine on experimental thrombosis and haemostasis. Bergqvist D; Nilsson B Thromb Haemost; 1987 Oct; 58(3):893-5. PubMed ID: 2829377 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses. Monreal L; Villatoro AJ; Monreal M; Espada Y; Anglés AM; Ruiz-Gopegui R Am J Vet Res; 1995 Oct; 56(10):1281-5. PubMed ID: 8928943 [TBL] [Abstract][Full Text] [Related]